Analytical Data
-
Gene name
Ab1-42
- Application
-
Alternative Names
Ab1-42；Large ribosomal subunit Protein eL29
-
Species
Human
-
Source
E. coli
-
Tag
N-6His+SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P05067
-
Expression Region
1-42aa
-
AA Sequence
DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
-
Molecular Weight
20.5kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Identification
Protein Description
The study of the Ab1-42 recombinant protein is deeply rooted in Alzheimer's disease research, as this peptide is a significant component of amyloid plaques, which are characteristic of this neurodegenerative disorder. Ab1-42 is a derivative of the amyloid precursor protein (APP) and is known for its propensity to aggregate into fibrils, contributing to neuronal toxicity and cognitive decline observed in Alzheimer’s patients. Understanding the structure, aggregation dynamics, and biological effects of Ab1-42 is crucial for elucidating the pathophysiological mechanisms underlying the disease. Recombinant expression systems have been developed to produce Ab1-42 in a controlled manner, allowing for detailed biochemical and biophysical studies. These investigations aim to elucidate the mechanisms of aggregation, identify potential therapeutic targets, and evaluate the peptide's interactions with biological membranes and cellular components. Research has also focused on the development of inhibitors that can prevent Ab1-42 aggregation or promote its clearance, representing a potential avenue for therapeutic intervention. By gaining insights into the fundamental properties of Ab1-42, researchers hope to pave the way for innovative treatments that could mitigate or prevent the progression of Alzheimer’s disease, ultimately improving the quality of life for patients and their families.
